Search results for:
mirikizumab-mrkz
mirikizumab-mrkz
| Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
| Omvoh |
INJECTION, INTRAVENOUS |
20 mg/mL | 100 mg/mL |
|
|
|
|
| Omvoh |
INJECTION, SUBCUTANEOUS |
100 mg/mL | 200 mg/mL |
|
|
|
|
Last updated: Jun. 12, 2025
Non-formulary. Use or initiation should be deferred to the non-hospital outpatient setting. Alternative agents are available to treat ulcerative colitis in the outpatient setting.
Reviewed: May 2025
Mirikizumab-mrkz (OMVOH) Spotlight.pdf